• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

DNDi calls on G8 leaders to increase their commitment to neglected tropical diseases

Geneva, Switzerland — 26 Jun 2008
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

Immediately following the Drugs for Neglected Diseases initiative (DNDi) Stakeholders’ Meeting on June 26, 2008, and in advance of the upcoming 2008 G8 Summit in Japan, DNDi released a statement endorsed by World Health Organization (WHO) urging the G8 governments to support both control programs and research & development (R&D) initiatives for neglected tropical diseases.

New and better-adapted treatments and diagnostics are needed for chronically endemic tropical diseases that have a significant impact on the lives of the poor, yet are neglected by the global public health agenda.

The statement calls upon the world’s wealthiest nations “to commit resources for appropriate and sustainable financial mechanisms to strengthen existing efforts and to support innovation required to meet the priority health needs of developing countries.”

For some of the neglected tropical diseases, large programs supported by public-private partnerships, including drug donations, provide effective and safe medicines which can be administered to at-risk populations with the aim of eventually eliminating the disease. Despite the fact that many low-cost and effective interventions are available to control some of these diseases, the majority of affected populations still do not have access due to lack of resources.

Furthermore, research is needed for new, practical and effective diagnostics and medicines. As the microbial world is constantly evolving, even the best control tools can lose their power if drug resistance develops or disease patterns change. Long-term investment is essential to develop better medicines, to prevent resistance, and to ensure sustainability.

Thus, DNDi urges the active participation of public institutions from developed countries to assist their counterparts in the developing world. According to Dr. Bernard Pécoul, DNDi’s Executive Director, “In order for the needs of neglected patients to be met, countries of the G8 must take measures to ensure that investment in research goes hand-in-hand with control program support.”

The full text of the statement is available below.

About DNDi

DNDi is an independent, non-profit product development partnership working to research and develop new and improved treatments for neglected diseases such as malaria, leishmaniasis, sleeping sickness and Chagas Disease. With the objective to address unmet patient needs for these diseases, DNDi has developed the largest ever portfolio for the kinetoplastid diseases and has already released two new antimalarial medicines. The  DNDi founding members are 5 research institutions: Institut Pasteur, Kenya Medical Research Institute (KEMRI), Indian Council of Medical Research (ICMR), the Foundation Oswaldo Cruz in Brazil, the Ministry of Health in Malaysia, and the humanitarian organisation Médecins sans Frontières. The special Programme for Research and Training in Tropical Diseases (TDR) from WHO/UNICEF/World Bank acts as a permanenent observer to the initiative.  For further information, please visit: www.dndi.org.

Joint DNDi and WHO Statement
Neglected tropical diseases continue to affect more than 1 billion people all over the world
Geneva – June 30, 2008 – Infectious and parasitic diseases – most of which are preventable and/or treatable – remain the primary cause of death worldwide. International attention is currently focused on HIV/AIDS, malaria, and tuberculosis, as well as on global health security. However, many other chronically endemic tropical diseases, which have a very significant negative impact on the lives of poor populations, are still very much neglected by the global public health agenda.
Most neglected tropical diseases(1) primarily affect poor and marginalized people who have few resources or possibilities to make a living. In developing countries, these diseases affect individuals, families, and entire communities. The high burden of disease and loss of productivity aggravate poverty and contribute to high cost of long-term care.  Socioeconomic development and quality of life is affected at all levels. Improved control and prevention of these diseases will help to alleviate poverty and to reach the Millennium Development Goals.
For some of the neglected tropical diseases, large programmes supported by effective partnerships, including drug donations, provide effective and safe medicines which can be administered to at-risk populations in order to eventually eliminate the disease. Despite the fact that many low-cost and effective interventions are available to control some of these diseases, the majority of affected populations still do not have access to them due to a lack of resources.
Other diseases such as human African trypanosomiasis, Chagas disease, leishmaniasis, and Buruli ulcer, present the greatest challenge for intensified control because no adequate tools exist: effective and adapted options for prevention, diagnosis, and treatment are needed.
Research is needed for new, practical and effective improved diagnostics and medicines and for effective ways to implement them. As the microbial world is constantly evolving, even the best control tools can lose their power if drug resistance develops or disease patterns change. Long-term investment is essential to develop better medicines, to prevent resistance, and to ensure this is not a one-off achievement.
Demanding technical requirements of existing therapeutic tools limit their use and require long hospital stays, with devastating consequences on livelihoods (particularly in subsistence-farming areas). Until simpler and safer drugs are developed, control efforts must remain extremely resource intensive and poorly suited to strategies for reaching those most in need.
Despite ongoing efforts of existing product development partnerships, the inadequacies of existing tools and of infrastructures to deliver them remain major constraints.
Patients deserve affordable and safe diagnostics and treatment. To control these diseases and to have an impact on health and poverty, investment in long-term research must go hand in hand with program support. Doing so will help fulfil the promise of ongoing positive trends, including the conviction – underlying many research, control, and intervention partnerships – that neglected tropical diseases can be eliminated when the world’s best tools and methodologies are made available to all at-risk populations.
In preparation for the 2008 G8 Summit in Japan, we ask you to support official inclusion of the following statement:
“Recognizing the importance of neglected diseases as global health, educational, and economic threats in developing countries, the G8 commits to support both neglected diseases’ control programs and research & development initiatives to develop new and better adapted treatments and diagnostics. Further to this, the G8 commits to recommend appropriate, sustainable financial mechanisms to strengthen existing efforts and to support innovation required to meet the priority health needs of developing countries.”

(1) The 13 parasitic and bacterial infections known as the neglected tropical diseases include three soil-transmitted helminthiasis (ascariasis, hookworm infections, and trichuriasis), lymphatic filariasis, onchocerciasis, dracunculiasis (guinea-worm disease), schistosomiasis, Chagas’ disease, human African trypanosomiasis, leishmaniasis, Buruli ulcer, leprosy, and trachoma. An expanded list could include dengue fever, the treponematoses, leptospirosis, strongyloidiasis, foodborne trematodiases, cysticercosis, and scabies, as well as other tropical infections.

Contact

Dr. Lorenzo Savioli
Director
Department of Control of Neglected Tropical Diseases

DNDi
Dr. Bernard Pécoul
Executive Director
Drugs for Neglected Diseases initiative

Policy advocacy

Read, watch, share

Loading...
Young man sitting in hospital setting
News
25 Jan 2023

It’s time medical innovation reached the 1.7 billion people affected by neglected tropical diseases: World NTD Day 2023

Film Poster Voices of Leishmaniasis: Shushi from India
Videos
25 Jan 2023

Voices of leishmaniasis: Shishu from India

Child receiving treatment
News
20 Jan 2023

DNDi’s 20th year of bringing the best science for the most neglected

Child affected by dengue and her mother at their home in Bangkok, Thailand.
Stories
16 Dec 2022

2022: Six advances in neglected disease research to remember

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Healthcare workers discussing in hospital setting
Press releases
1 Dec 2022

DNDi partners in a new NIHR-funded Global Health Research Group on HIV-associated Fungal Infections (IMPRINT)

Healthcare workers looking into microscopes
Press releases
30 Nov 2022

Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa

Journalists talking with healthcare workers
News
23 Nov 2022

DNDi media workshops – bringing together reporters and researchers to cover neglected disease research

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo